06/10/2026
The widely used Over-the-Counter (OTC) medication alli (Orlistat), intended to aid in weight management, has undergone a label modification recently approved by the Food and Drug Administration (FDA). This revision serves as a warning regarding the ‘Risk of Kidney Stones’ and ‘Kidney Injury’.
The revised label advises consumers to consult a healthcare provider prior to using alli if they have a history of kidney disease, kidney stones, or chronic kidney disease. Furthermore, the label change instructs consumers to discontinue use of alli and consult a doctor if symptoms of kidney injury or kidney stones manifest, such as back or groin pain, painful urination, hematuria, edema of the feet and legs, or decreased urination frequency.
To learn more visit:
https://www.fda.gov/drugs/drug-safety-communications/fda-approves-labeling-changes-over-counter-otc-weight-loss-drug-alli-orlistat-warn-risk-kidney?utm_medium=email&utm_source=govdelivery